Literature DB >> 482350

beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders.

H M Emrich, V Höllt, W Kissling, M Fischler, H Laspe, H Heinemann, D von Zerssen, A Herz.   

Abstract

Measurements of beta-endorphin-like immunoreactivity have been performed in CSF and plasma of patients with schizophrenia and other neuropsychiatric disorders. The detection limit of the RIA was between 20--50 pg/ml (6--15 fmole/ml). In CSF the quantity of beta-endorphin-like immunoreactivity ranges up to 65 pg/ml. The data from schizophrenics and other neuropsychiatric patients show no obvious deviation from the results in a control group of medical patients with normal CSF findings. In plasma the immunoreactive beta-endorphin-like material ranges up to 250 pg/ml. There is only a small tendency to higher values in schizophrenic patients, if compared with different types of neuroses and affective and organic psychoses. In a second series of experiments also this tendency could not be reproduced. In 9 electroconvulsive treatments an increase of blood beta-endorphin-like immunoreactivity was observed 7 times. A possible endorphinergic mechanism in the mode of action of electroconvulsion is hypothesized.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 482350     DOI: 10.1055/s-0028-1094620

Source DB:  PubMed          Journal:  Pharmakopsychiatr Neuropsychopharmakol        ISSN: 0031-7098


  10 in total

1.  Hemodialysis in schizophrenia. Results in three chronic cases.

Authors:  M Fischler; H M Emrich; W Kissling; D von Zerssen; H Riedhammer; H H Edel
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979

2.  The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.

Authors:  C Gramsch; H M Emrich; S John; S Haas; H Beckmann; M Zaudig; D von Zerssen
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

Review 3.  Enkephalins and Endorphins. Clinical, pharmacological and therapeutic implications.

Authors:  D L Copolov; R D Helme
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

Review 4.  Changes in beta-endorphin levels in response to aerobic and anaerobic exercise.

Authors:  L Schwarz; W Kindermann
Journal:  Sports Med       Date:  1992-01       Impact factor: 11.136

Review 5.  [Poison in the filter: implementing detoxification procedures in schizophrenia].

Authors:  Ekkehardt Kumbier
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

6.  A simplified radioimmunological method for the determination of human beta-endorphin in cerebrospinal fluid.

Authors:  H Przuntek; J P Stasch; M Graf; K W Pflughaupt; N Gropp; M Witteler
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

7.  Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects.

Authors:  I Gil-Ad; Z Dickerman; S Amdursky; Z Laron
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 8.  Neuropeptides in dopamine-containing regions of the brain.

Authors:  A Albanese; M C Altavista
Journal:  Ital J Neurol Sci       Date:  1984-12

Review 9.  Peptide neuroregulators: the opioid system as a model.

Authors:  J D Barchas; C Evans; G R Elliott; P A Berger
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec

10.  Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models.

Authors:  Akiyoshi Saitoh; Mitsuhiko Yamada
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.